Treatment options for chronic inflammatory demyelinating polyneuropathy include intravenous immunoglobulin, corticosteroids, plasmapheresis (plasma exchange), and a newer medication called Vyvgart ...

Treatment for chronic inflammatory demyelinating polyneuropathy can include intravenous immunoglobulin, corticosteroids, plasmapheresis, and Vyvgart Hytrulo.

Polyneuropathy can cause pain, discomfort, and mobility difficulties. Learn more about the types, causes, and symptoms, as well as how to diagnose and treat the condition.

Polyneuropathy Treatment Market Benefiting from Innovations in Neuromodulation Techniques and High Focus on Pain ManagementRockville, MD , Jan. 07, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a ...

Netherlands-based argenx has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended its efgartigimod alfa treatment, brand name ...

Since hATTR with polyneuropathy impacts several organs and is a genetic disease, you’ll likely have to see several specialists to manage the disease. Your care team can include: Genetic counselor.

2. AstraZeneca. Wainua (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults with Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis. Press Release.

Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that ...

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis ...

(Alliance News) - AstraZeneca PLC on Monday said its Wainzua treatment has been been recommended for EU approval to treat adult patients with polyneuropathy associated with hereditary ...

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...